Haroon Mohammad1, Kwaku Kyei-Baffour2, Nader S Abutaleb1, Mingji Dai3, Mohamed N Seleem4. 1. Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907, USA. 2. Department of Chemistry, Center for Cancer Research and Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, USA. 3. Department of Chemistry, Center for Cancer Research and Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, USA; Purdue Institute of Inflammation, Immunology, and Infectious Disease, 610 Purdue Mall, West Lafayette, IN 47907, USA. Electronic address: mjdai@purdue.edu. 4. Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907, USA; Purdue Institute of Inflammation, Immunology, and Infectious Disease, 610 Purdue Mall, West Lafayette, IN 47907, USA. Electronic address: mseleem@purdue.edu.
Abstract
OBJECTIVES: The aim of this study was to investigate the antibacterial activity of a synthetic aryl isonitrile compound (35) that was developed as part of a compound library to identify new antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). METHODS: Compound 35 was evaluated against MRSA isolates by the broth microdilution assay and for toxicity to mammalian keratinocytes using the MTS assay. A multistep resistance selection assay was conducted to investigate MRSA resistance development to 35. A Caco-2 bidirectional permeability assay was employed to evaluate the ability of 35 to permeate across the gastrointestinal tract, and compound 35 was incubated with human liver microsomes to determine susceptibility to hepatic metabolism. Finally, compound 35 was evaluated in an uncomplicated MRSA skin infection mouse model and an MRSA neutropenic thigh infection mouse model. RESULTS: Compound 35 inhibited the growth of MRSA clinical isolates at 2-4μM and was non-toxic to human keratinocytes. No resistance formation was observed with MRSA against compound 35 after 10 serial passages. In a murine skin wound model, compound 35 significantly reduced the burden of MRSA, similar to the antibiotic fusidic acid. Compound 35 exhibited a marked improvement both in permeability and stability to hepatic metabolism (half-life >11h) relative to the first-generation lead compound. In a neutropenic thigh infection mouse model, compound 35 successfully reduced the burden of MRSA in immunocompromised mice. CONCLUSION: In summary, compound 35 was identified as a new lead aryl isonitrile compound that warrants further investigation as a novel antibacterial agent.
OBJECTIVES: The aim of this study was to investigate the antibacterial activity of a synthetic aryl isonitrile compound (35) that was developed as part of a compound library to identify new antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). METHODS: Compound 35 was evaluated against MRSA isolates by the broth microdilution assay and for toxicity to mammalian keratinocytes using the MTS assay. A multistep resistance selection assay was conducted to investigate MRSA resistance development to 35. A Caco-2 bidirectional permeability assay was employed to evaluate the ability of 35 to permeate across the gastrointestinal tract, and compound 35 was incubated with human liver microsomes to determine susceptibility to hepatic metabolism. Finally, compound 35 was evaluated in an uncomplicated MRSA skin infectionmouse model and an MRSA neutropenic thigh infectionmouse model. RESULTS: Compound 35 inhibited the growth of MRSA clinical isolates at 2-4μM and was non-toxic to human keratinocytes. No resistance formation was observed with MRSA against compound 35 after 10 serial passages. In a murine skin wound model, compound 35 significantly reduced the burden of MRSA, similar to the antibiotic fusidic acid. Compound 35 exhibited a marked improvement both in permeability and stability to hepatic metabolism (half-life >11h) relative to the first-generation lead compound. In a neutropenic thigh infectionmouse model, compound 35 successfully reduced the burden of MRSA in immunocompromised mice. CONCLUSION: In summary, compound 35 was identified as a new lead aryl isonitrile compound that warrants further investigation as a novel antibacterial agent.
Authors: Anthony D Wright; Adam McCluskey; Mark J Robertson; Kylie A MacGregor; Christopher P Gordon; Jana Guenther Journal: Org Biomol Chem Date: 2010-11-02 Impact factor: 3.876
Authors: David J Farrell; Marion Robbins; William Rhys-Williams; William G Love Journal: Antimicrob Agents Chemother Date: 2010-12-13 Impact factor: 5.191
Authors: T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis Journal: N Engl J Med Date: 1999-02-18 Impact factor: 91.245
Authors: Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin Journal: Infect Control Hosp Epidemiol Date: 2012-11-27 Impact factor: 3.254
Authors: A Russo; E Concia; F Cristini; F G De Rosa; S Esposito; F Menichetti; N Petrosillo; M Tumbarello; M Venditti; P Viale; C Viscoli; M Bassetti Journal: Clin Microbiol Infect Date: 2016-04 Impact factor: 8.067
Authors: Mohamed M Elsebaei; Haroon Mohammad; Mohamed Abouf; Nader S Abutaleb; Youssef A Hegazy; Adel Ghiaty; Lu Chen; Jianan Zhang; Satish R Malwal; Eric Oldfield; Mohamed N Seleem; Abdelrahman S Mayhoub Journal: Eur J Med Chem Date: 2018-02-12 Impact factor: 6.514
Authors: George A Naclerio; Kenneth I Onyedibe; Caroline W Karanja; Uma K Aryal; Herman O Sintim Journal: ACS Infect Dis Date: 2022-03-17 Impact factor: 5.578
Authors: George A Naclerio; Nader S Abutaleb; Kenneth I Onyedibe; Caroline Karanja; Hassan E Eldesouky; Hsin-Wen Liang; Alexandra Dieterly; Uma K Aryal; Tiffany Lyle; Mohamed N Seleem; Herman O Sintim Journal: J Med Chem Date: 2022-04-28 Impact factor: 8.039